Human cytomegalovirus (HCMV) can cause severe disease in patients with compromised or
immature immune systems. Currently approved pharmacotherapies for the treatment of …

Human cytomegalovirus (HCMV) is a major cause of morbidity and mortality for
immunocompromised hosts. We sought to determine the in vitro susceptibility of HCMV …

This study describes the extent of cross-resistance and interactions for selected inhibitors of
human cytomegalovirus (HCMV) DNA synthesis and DNA processing. HCMV isolates …

This editorial summarizes recent developments in the management of ganciclovir-resistant
human cytomegalovirus (HCMV) infections. All current drugs available for systemic …

This review discusses the management of resistant cytomegalovirus and prevention
strategies for fatal therapy failures. Five drugs, ganciclovir/valganciclovir, cidofovir, foscarnet …

Human cytomegalovirus (HCMV) infections are usually benign and self-limiting in the
immunocompetent population; however, HCMV is a well-recognized problem among …

Conventional therapy for human cytomegalovirus (CMV) relies on inhibition of the viral DNA
polymerase. Ganciclovir (GCV) is the first-line therapy, but when GCV-resistant strains …

Cytomegalovirus (CMV) is an opportunistic pathogen associated with significant morbidity
and mortality in immunocompromised hosts. Antiviral agents specifically targeting CMV were …

The recent approval of letermovir marks a new era of therapy for human cytomegalovirus
(HCMV) infections, particularly for the prevention of HCMV disease in hematopoietic stem …

The study of human cytomegalovirus (HCMV) antiviral drug resistance has enhanced
knowledge of the virological targets and the mechanisms of antiviral activity. The currently …